MRNA Pulls Back from Highs Despite Plans to Up Vaccine Doses

The equity sports an over 739% year-over-year lead, though

Digital Content Manager
Feb 1, 2021 at 10:35 AM
facebook twitter linkedin

The shares of Moderna Inc. (NASDAQ:MRNA) are lower this morning, last seen down 4.5% at $165.34, despite reports that the biopharmaceutical concern is attempting to get authorization from the Food and Drug Administration (FDA) to raise the number of doses in its Covid-19 vaccine vials to 15 from 10. The firm also received a pair of price-target hikes earlier today from Oppenheimer and SVB Leerink, to $206 and $80, respectively.

Digging deeper, the security has been tearing up the charts since cooling off from its early December peak, bouncing off the supportive 60-day moving average to score a Jan. 29 all-time high of $185.98. Year-over-year, MRNA sports an impressive 739.7% lead.

Analysts were mostly pessimistic towards the equity coming into today. Of the 14 in question, eight carried a tepid "hold" or worse rating, while six said "strong buy." Plus, the 12-month consensus target price of $148.92 is a 14% discount to current levels.

Shorts are building their positions, too. Short interest rose roughly 6% in the most recent reporting period, and now the 24.80 million shares sold short account for a significant 7.6% of the stock's available float, or over a days' worth of pent-up buying power.

The options pits echo that pessimism, with puts popular. This is per Moderna stock's 50-day put/call volume ratio at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than 93% of readings from the past year. This means puts are being picked up at a quicker-than-usual pace.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners